Overall increase is small, though, adding 1 cancer per 1,000 women treated
by solovemymom on Thu Nov 03, 2011 07:34 PM
I'm praising God and want to urgently share the fantastic response my Mom is having to Phase ll Clinical Trial of antibody BMS-936558. My Mom is battling Metatastic RCC and was previously on Sutent, Nexavar, and Votrient. She has been on this clinical trial for 12 weeks and has had a significant response including some tumors are no longer visible and others have shrunk 50-70% !!! She also has had little to no side effects, is 67 years young and still working ! I believe many of you have a good chance at qualifying for this trial as you must have been on at least 1 prior Antio-Angiogenic Therapy with cancer progression, but not more than 3 of these therapies. Examples are Sutent, Nexavar, Votrient and I believe also Afinitor. I urge you all to go to ClinicalTrials.gov and search for trial identifier NCT01354431 to read more about this trial and see if there is a partipating location near you. Please let me know if you have questions.
God Bless You All,
by MamaB on Fri Nov 11, 2011 04:36 AM
I am so glad your Mom has found something to help her! Thank you so very much for sharing this information on the forum, there are so many people out there that need a miracle!
I was diagnosed with Stage IV RCC with lung mets in 2007. For two and a half years I took Sutent 50mg, 28 days on and 14 off. Then, my kidney was removed. The Sutent was stopped a month before surgery and I have not taken any more cancer drugs. It has been 20 months since the surgery. I just had another set of scans and lab work this week; there was no cancer!
God is so awesome! Without my Faith and all the answered prayers, I don't think I would have made it.
It is good to know the Researches are constantly coming up with new ideas to hopefully wipe out this monster thing called Renal Cell Cancer.
I wish your mom the very best and I hope she can soon put all of this behind her and get on with her life.
Again, thank you so much for sharing and please keep us posted on your mom's progress.
by solovemymom on Wed Nov 16, 2011 10:47 PM
Without a doubt our God is AWESOME !!! I'm so very happy for you !!! Thank you for the well wishes for my Mom !!!
May God Bless You and keep you in His care always !!!
by SusanJS on Fri Dec 09, 2011 02:02 AM
We are told that this study is now closed to enrolment. Despite having signed the consent in mid October, and having planned to receive his infusion today, we are now informed the study is closed. Can anyone tell us if it is indeed closed to enrolment and when that happened? There seems to have been some "ball dropping" from the team here that may have resulted in missing a window of opportunity.
by sstar280 on Sat Feb 25, 2012 04:16 PM
Try following this link - this is the trial I am in screening for and it is dosage study of the same clinical trialDose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
God Bless you and good luck.
by brookep on Tue Mar 13, 2012 10:07 PM
That is AWEsome!!! Continued good luck to you!
My husband's advanced cancer is of the Papillary type, so he doesn't qualify for this one. We are screwed out of most studies because of this. If anyone hears of anything, please let me know!!
by Rnrnc on Sat Mar 17, 2012 02:37 AM
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
If you were considering traveling for cancer treatment, which headline would you find more interesting?
Destination: HOPE. Cancer care that is worth the trip.
Over 84% of our patients travel to our hospital from another state
Neither headline is interesting
We care about your feedback. Let us know how we can improve your CancerCompass experience.